TY - BOOK ID - 101913049 TI - Gluten-Related Disorders: Time to Move from Gut to Brain AU - Hoggard, Nigel AU - Sanders, David AU - Hadjivassiliou, Marios PY - 2022 SN - 3036550607 3036550593 PB - MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - Research & information: general KW - Biology, life sciences KW - Food & society KW - coeliac disease KW - gluten free diet KW - psychiatric manifestations KW - autistic spectrum disorder KW - attention deficit hyperactivity disorder KW - depression KW - anxiety KW - bipolar disorder KW - schizophrenia KW - eating disorders KW - gluten KW - neurological disorders KW - gliadin KW - ataxia KW - neuropathy KW - myopathy KW - encephalopathy KW - food intolerance KW - celiac disease KW - gluten sensitivity KW - gluten-free diet KW - cognition KW - neurology KW - disease duration KW - autoimmunity KW - multiple sclerosis KW - psoriasis KW - autoimmune thyroid disease KW - type 1 diabetes KW - transglutaminase antibodies KW - TG2 KW - TG3 KW - TG6 KW - dermatitis herpetiformis KW - gluten ataxia KW - gluten encephalopathy KW - gluten neuropathy KW - autism spectrum disorder KW - review KW - stiff person syndrome KW - anti-GAD antibodies KW - cerebellar ataxia KW - gluten-related pathology KW - cortical excitability KW - transcallosal inhibition KW - transcranial magnetic stimulation KW - executive dysfunction KW - gamma-amino-butyric acid KW - neurological dysfunction KW - headaches KW - anti-gliadin antibodies KW - MR imaging KW - TG6 antibodies KW - non-celiac wheat sensitivity KW - irritable bowel syndrome KW - multiple food hypersensitivity KW - neuropsychiatric symptoms KW - HLA KW - duodenal lymphocytosis UR - https://www.unicat.be/uniCat?func=search&query=sysid:101913049 AB - The extraintestinal manifestations of coeliac disease (CD) are now well recognised. We have previously edited a special issue for Nutrients covering all aspects of the extraintestinal manifestations in the context of CD. In this issue we wish to concentrate just on the neurological manifestations. The identification of TG6 autoantibodies in patients with neurological manifestations and its use in the diagnosis of such patients seems to be a good opportunity to focus on the neurological aspect of CD. In addition it is now clear that such manifestations can occur even in the absence of enteropathy but in the presence of antigliadin antibodies and/or TG6 antibodies. Given that such antigliadin antibodies can be found in up to 10% of the “healthy” population we anticipate that the neurological manifestations are likely to be very common and thus merit early recognition and treatment. ER -